We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.60 | 9.40 | 9.80 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.44 | 89.07M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Presenting at the Annual Immuno-Oncology Summit |
| 16/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Block Listing Six Monthly Return |
| 03/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Employee exercise of share options |
| 02/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Scancell to Present at 2024 AACR Annual Meeting |
| 28/3/2024 | 13:21 | UK RNS | Scancell Holdings Plc Scancell Appoints WG as Joint Broker |
| 26/3/2024 | 14:00 | ALNC |  Scancell doses first patient in melanoma-focused trials |
| 26/3/2024 | 12:22 | UK RNS | Scancell Holdings Plc First iSCIB1+ patient dosed |
| 14/3/2024 | 11:17 | UK RNS | Scancell Holdings Plc Appointment of Sath Nirmalananthan to the Board |
| 12/3/2024 | 07:00 | UK RNS | Scancell Holdings Plc Scancell Attendance at Upcoming Conferences |
| 04/3/2024 | 07:00 | UK RNS | Scancell Holdings Plc Presenting at Next-Gen Immuno-Oncology Conference |
1 Year Scancell Chart |
Intraday Scancell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
